Study Predicts Infant Risk Exposure to Mother’s Medications
The study is the first to examine drug exposure in both the womb and breast milk.
Complete the form below to unlock access to ALL audio articles.
A new mathematical model developed at the University of Waterloo can determine a baby’s overall drug exposure when their mother is taking medication. This is the first study to include drug transfer from the umbilical cord and through breastfeeding in determining the baby's total drug levels.
The research team from the School of Pharmacy at Waterloo looked specifically at Levetiracetam. It is a drug commonly prescribed long-term for women with epilepsy, yet there was minimal data on the risk of adverse effects on breastfed infants.
Breastfeeding mothers often face the hard choice of continuing to take their medication and risking harm to their babies due to exposure during feeding or stopping potentially life-saving treatments. The World Health Organization and UNICEF recommend that infants breastfeed within an hour of birth and do so exclusively for six months.
Want more breaking news?
Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.
Subscribe for FREEThe team built the mathematical model using physiologically based pharmacokinetic (PBPK) modeling, to determine the overall infant exposure to the drug.
“We included both womb and breast milk exposure in our newborn-infant model, which we’ve coined the cord-coupled model (CCM), to gain a more accurate picture of drug exposure to infants during their most vulnerable time in the first weeks of life,” Wang said.
“We also included in the PBPK model infant anatomy and physiology, the volume of breast milk consumed and the drug concentrations in breast milk for more accurate results,” said Dr. Santosh Suryavanshi, research associate at the School of Pharmacy.
Clinical data for infants is still lacking for many drugs. The study’s model can help in the assessment of other commonly prescribed drugs that breastfeeding mothers might take.
“There has always been limited data in specific populations due to the risks associated with clinical trials,” Suryavanshi said. “This mathematical modelling is a tool researchers can use to determine drug exposures to improve the quality of life for both mother and infant.”
The study, Coupling Pre‑ and Postnatal Infant Exposures with Physiologically Based Pharmacokinetic Modeling to Predict Cumulative Maternal Levetiracetam Exposure During Breastfeeding, was recently published in Clinical Pharmacokinetics.
Reference: Suryavanshi SV, Wang S, Hajducek DM, et al. Coupling pre- and postnatal infant exposures with physiologically based pharmacokinetic modeling to predict cumulative maternal levetiracetam exposure during breastfeeding. Clin Pharmacokinet. 2024;63(12):1735-1748. doi: 10.1007/s40262-024-01447-3
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.
